Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.tarsons.com | |
Market Cap | 3,636.38 Cr. | |
Enterprise Value(EV) | 3,633.05 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 17.42 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 39.22 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 19.92 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 99.95 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 6.84 | Calculated using Price: 683.45 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 5.32 Cr. | 53,206,281 Shares |
FaceValue | 2 | |
Company Profile | ||
Tarsons Products is an Indian labware company engaged in the designing, development, manufacturing and marketing of ‘consumables’, ‘reusables’ and ‘others’ including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, Contract Research Organizations (CROs), Diagnostic companies and hospitals. It manufactures a range of quality labware products which helps advance scientific discovery and improve healthcare. The company’s product portfolio is classified into three key categories which include consumables, reusables, and others. ‘Consumables’ category includes products such as centrifuge ware, cryogenic ware, liquid handling, PCR consumables and petri dish, transfer pipettes and others. ‘Reusables’ category includes products such as bottles, carboys, beakers, measuring cylinders and tube racks. ‘Others’ category includes benchtop instrumentation such as vortex shakers, centrifuges pipettors and others. |
1 Day |
|
-0.94% |
1 Week |
|
-1.86% |
1 Month |
|
-1.95% |
3 Month |
|
-14.81% |
6 Month |
|
-10.48% |
1 Year |
|
+3.64% |
2 Year |
|
|
5 Year |
|
|
10 Year |
|
4 years | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 28.80 | 24.35 | 31.17 | 27.42 | |
Return on Capital Employed (%) | 31.57 | 27.35 | 37.22 | 35.28 | |
Return on Assets (%) | 18.38 | 17.60 | 21.51 | 18.90 |
Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 135 | 198 | 244 | 490 | 532 | |
Non Curr. Liab. | 23 | 11 | 106 | 149 | 22 | |
Curr. Liab. | 54 | 40 | 42 | 35 | 75 | |
Minority Int. | ||||||
Equity & Liab. | 212 | 249 | 392 | 673 | 629 | |
Non Curr. Assets | 115 | 129 | 279 | 429 | 395 | |
Curr. Assets | 97 | 120 | 113 | 245 | 233 | |
Misc. Exp. not W/O | ||||||
Total Assets | 212 | 249 | 392 | 673 | 629 |
Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 179 | 176 | 229 | 301 | 295 | |
Other Income | 6 | 5 | 5 | 8 | 11 | |
Total Income | 185 | 181 | 234 | 309 | 307 | |
Total Expenditure | -107 | -108 | -125 | -148 | -154 | |
PBIDT | 78 | 73 | 109 | 161 | 153 | |
Interest | -7 | -6 | -3 | -4 | -3 | |
Depreciation | -15 | -14 | -14 | -22 | -26 | |
Taxation | -17 | -13 | -24 | -34 | -31 | |
Exceptional Items | ||||||
PAT | 39 | 41 | 69 | 101 | 93 | |
Adjusted EPS | 14 | 19 | 17 |
Particulars | 4 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 51 | 64 | 68 | 83 | |
Cash Fr. Inv. | -34 | -25 | -64 | -138 | |
Cash Fr. Finan. | -18 | -14 | -27 | 130 | |
Net Change | 0 | 25 | -23 | 75 | |
Cash & Cash Eqvt | 1 | 25 | 2 | 77 |
Fri, 06 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 We are enclosing herewith a Certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulations 2018 for the quarter ended 31st December 2022 as received from M/s. KFin Technologies Limited Registrar and Transfer Agent of the Company. |
Tue, 27 Dec 2022
Closure of Trading Window This is to inform you that in terms of Companys Code of Conduct for Regulating Monitoring and Reporting of Trading by Insiders read with SEBI (Prohibition of Insider Trading) Regulations 2015 the Trading Window for dealing in the securities of the Company will remain closed for all Designated Persons and their immediate relatives with effect from 1st January 2023 until 48 hours after the declaration and dissemination of the Unaudited Financial Results of the Company to the Stock Exchanges for the third quarter and nine months ended 31st December 2022. Accordingly all the Directors/ Designated Persons of the Company have been informed to not trade in the securities of the Company during the aforesaid period of closure of Trading Window.The details of the Board meeting for consideration of the financial results shall be intimated in due course.Kindly take the above on your records. |
Wed, 07 Dec 2022
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation of Schedule of Analyst/Institutional Investor Meeting pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 to be held on Thursday 8th December 2022 at 01:00 P.M. |
Fri, 27 Jan 2023 |
|
|
|
|
|